Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

H. Moskowitz, Craig; Walewski, Jan; Nademanee, Auayporn; Masszi, Tamás; Agura, Edward; Hołowiecki, Jerzy; H. Abidi, Muneer; I. Chen, Andy; J. Stiff, Patrick; Viviani, Simonetta; Bachanová, Veronika; Sureda, Anna; McClendon, Teresa; Lee, Connie; Lisano, Julie; Sweetenham, John

doi:10.1182/blood-2018-07-861641

Public

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Published in Blood • Sep 28, 2018

Authors:

Craig H. Moskowitz

Jan Walewski

Auayporn Nademanee

Abstract

The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression after autologous hematopoietic stem-cell transplantation (auto-HSCT). Results showed that BV significantl...

Subject

Brentuximab vedotin

Medicine

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!